166 related articles for article (PubMed ID: 2550402)
1. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men.
Rittmaster RS; Stoner E; Thompson DL; Nance D; Lasseter KC
J Androl; 1989; 10(4):259-62. PubMed ID: 2550402
[TBL] [Abstract][Full Text] [Related]
2. Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans.
Vermeulen A; Giagulli VA; De Schepper P; Buntinx A; Stoner E
Prostate; 1989; 14(1):45-53. PubMed ID: 2538808
[TBL] [Abstract][Full Text] [Related]
3. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
[TBL] [Abstract][Full Text] [Related]
4. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Wallace AM; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
[TBL] [Abstract][Full Text] [Related]
5. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.
Gormley GJ; Stoner E; Rittmaster RS; Gregg H; Thompson DL; Lasseter KC; Vlasses PH; Stein EA
J Clin Endocrinol Metab; 1990 Apr; 70(4):1136-41. PubMed ID: 2156887
[TBL] [Abstract][Full Text] [Related]
6. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
7. Androgen glucuronyl transferase activity in rat liver, evidence for the importance of hepatic tissue in 5 alpha-reduced androgen metabolism.
Rittmaster RS; Leopold CA; Thompson DL
J Steroid Biochem; 1989 Dec; 33(6):1207-12. PubMed ID: 2615365
[TBL] [Abstract][Full Text] [Related]
8. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat.
George FW; Johnson L; Wilson JD
Endocrinology; 1989 Nov; 125(5):2434-8. PubMed ID: 2551651
[TBL] [Abstract][Full Text] [Related]
9. Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5 alpha-reductase inhibitor.
De Schepper PJ; Imperato-McGinley J; Van Hecken A; De Lepeleire I; Buntinx A; Carlin J; Gressi MH; Stoner E
Steroids; 1991 Sep; 56(9):469-71. PubMed ID: 1666698
[TBL] [Abstract][Full Text] [Related]
10. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone suppressibility and adrenal and ovarian venous effluents of 5α-reduced C19 conjugates in hyperandrogenic women.
Stanczyk FZ; Saxena T; Lobo RA
J Steroid Biochem Mol Biol; 2014 Jan; 139():73-7. PubMed ID: 24121067
[TBL] [Abstract][Full Text] [Related]
12. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
[TBL] [Abstract][Full Text] [Related]
13. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
Imperato-McGinley J; Shackleton C; Orlic S; Stoner E
J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
[TBL] [Abstract][Full Text] [Related]
14. A simple, differential extraction method for the simultaneous direct radioimmunoassay of androgens and androgen glucuronides in human serum.
Brind J; Borofsky N; Chervinsky K; Vogelman JH; Orentreich N
Steroids; 1996 Jul; 61(7):429-32. PubMed ID: 8837296
[TBL] [Abstract][Full Text] [Related]
15. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327.
Brooks JR; Berman C; Nguyen H; Prahalada S; Primka RL; Rasmusson GH; Slater EE
Prostate; 1991; 18(3):215-27. PubMed ID: 1850515
[TBL] [Abstract][Full Text] [Related]
16. Preferential metabolism of dihydrotestosterone to androstanediol 17-glucuronide in rat prostate.
Rittmaster RS; Leopold CA; Thompson DL
Endocrinology; 1988 Dec; 123(6):2788-92. PubMed ID: 3143543
[TBL] [Abstract][Full Text] [Related]
17. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.
Labrie F; Bélanger A; Cusan L; Candas B
J Clin Endocrinol Metab; 1997 Aug; 82(8):2403-9. PubMed ID: 9253308
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of dihydrotestosterone to 5 alpha-androstane-3 alpha, 17 beta-diol glucuronide is greater in the peripheral compartment than in the splanchnic compartment.
Duffy DM; Legro RS; Chang L; Stanczyk FZ; Lobo RA
Fertil Steril; 1995 Oct; 64(4):736-9. PubMed ID: 7672144
[TBL] [Abstract][Full Text] [Related]
19. Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.
Schwartz JI; Van Hecken A; De Schepper PJ; De Lepeleire I; Lasseter KC; Shamblen EC; Winchell GA; Constanzer ML; Chavez CM; Wang DZ; Ebel DL; Justice SJ; Gertz BJ
J Clin Endocrinol Metab; 1996 Aug; 81(8):2942-7. PubMed ID: 8768856
[TBL] [Abstract][Full Text] [Related]
20. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B
Prostate; 1993; 22(1):43-51. PubMed ID: 8381228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
